Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Alexander Benet"'
Autor:
Jill Coghlan, Alexander Benet, Preethi Kumaran, Michael Ford, Lawrie Veale, St. John Skilton, Sergei Saveliev, Anna A. Schwendeman
Publikováno v:
Frontiers in Bioengineering and Biotechnology, Vol 10 (2022)
Post translational modifications (PTMs) have been shown to negatively impact protein efficacy and safety by altering its native conformation, stability, target binding and/or pharmacokinetics. One PTM in particular, shuffled disulfide bonds, has been
Externí odkaz:
https://doaj.org/article/16e26e87fd4d48209bbd271a8751d045
Autor:
Alexander Benet, Troy Halseth, Jukyung Kang, April Kim, Rose Ackermann, Santhanakrishnan Srinivasan, Steven Schwendeman, Anna Schwendeman
Publikováno v:
Pharmaceutics, Vol 13, Iss 8, p 1263 (2021)
Exenatide, a glucagon-like peptide-1 receptor agonist, is the active pharmaceutical ingredient in Byetta® and Bydureon®, two type 2 diabetes drug products that have generics and multiple follow-up formulations currently in development. Even though
Externí odkaz:
https://doaj.org/article/cfdddcbf97ef416498e9b3f921369de4
Autor:
Steven P. Schwendeman, Bin Qin, Justin K Y Hong, Yan Wang, Alexander Benet, Jennifer Walker, Avital Beig, Jukyung Kang, Aishwarya Chandrashekar, Anna Schwendeman, Tinghui Li, Rose Ackermann
Publikováno v:
European Journal of Pharmaceutics and Biopharmaceutics. 158:401-409
Bydureon® (Bdn) is a once-weekly injectable long-acting release (LAR) product for adults with type 2 diabetes based on PLGA microspheres encapsulating the glucagon like peptide (GLP-1) analog, exenatide. Despite its widespread use in type 2 diabetes
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::85086dc3f3c3d1b9afa32012171c69cb
https://doi.org/10.1016/j.ejpb.2020.10.008
https://doi.org/10.1016/j.ejpb.2020.10.008
Autor:
Steven P. Schwendeman, Jukyung Kang, Solomon Z. Okbazghi, Yuwei Tian, Anna Schwendeman, Michael J. Ford, Eric Carlson, K. Ilker Sen, Thomas J. Tolbert, Karthik Pisupati, Alexander Benet, Brandon T. Ruotolo, Sergei Saveliev
Publikováno v:
mAbs. 9:1197-1209
Remsima™ (infliximab) is the first biosimilar monoclonal antibody (mAb) approved by the European Medical Agency and the US Food and Drug Administration. Remsima™ is highly similar to its reference product, Remicade®, with identical formulation c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3168c25bc5d17c44f3ed1e497bae1299
https://doi.org/10.1080/19420862.2017.1347741
https://doi.org/10.1080/19420862.2017.1347741
Autor:
Thomas J. Tolbert, Brandon T. Ruotolo, Christopher M. Hosfield, Yuwei Tian, Anna Schwendeman, Rose Ackermann, Christopher H. Becker, Solomon Z. Okbazghi, Marjeta Urh, Alexander Benet, Steven P. Schwendeman, Sergei Saveliev, Karthik Pisupati, Michael J. Ford, Eric Carlson
Publikováno v:
Analytical Chemistry. 89:4838-4846
In April 2016, the Food and Drug Administration approved the first biosimilar monoclonal antibody (mAb), Inflectra/Remsima (Celltrion), based off the original product Remicade (infliximab, Janssen). Biosimilars promise significant cost savings for pa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::be897ef319c52ec2cd4c6898e8fc3ef6
https://doi.org/10.1021/acs.analchem.6b04436
https://doi.org/10.1021/acs.analchem.6b04436
Autor:
Tyler S. Hageman, Jill Coghlan, Derek R. White, K. Ilker Sen, Anna Schwendeman, Jukyung Kang, Steven P. Schwendeman, Sergei Saveliev, Alexander Benet, Michael J. Ford, Thomas J. Tolbert, Brandon T. Ruotolo, Sang Yeop Kim, David D. Weis, Daniel D. Vallejo
Publikováno v:
European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V. 146
Biosimilars are poised to reduce prices and increase patient access to expensive, but highly effective biologic products. However, questions still remain about the degree of similarity and scarcity of information on biosimilar products from outside o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5789c0cb739018af019c6aa816cf0f7b
https://pubmed.ncbi.nlm.nih.gov/31841688
https://pubmed.ncbi.nlm.nih.gov/31841688
Autor:
Jukyung Kang, Alexander Benet, Steven P. Schwendeman, Karthik Pisupati, Brandon T. Ruotolo, Anna Schwendeman
Publikováno v:
Trends in biotechnology. 36(10)
Structural and functional differences between REMICADE and its two FDA-approved biosimilars appear to have clinical implications. We suggest a personalized biosimilar substitution approach based on prescribed indication, biosimilar afucosylation leve
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::be2945b41d41182e2be2fd94ec88c8b2
https://pubmed.ncbi.nlm.nih.gov/29861288
https://pubmed.ncbi.nlm.nih.gov/29861288